Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese drugmaker is reworking parts of its operations in the U.S. Eisai plans to ...

The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...

(MENAFN- JCN NewsWire) "Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" - Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and ...

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. Pfizer has formed a clinical trial ...

It's too early to talk about sending troops to Ukraine, Riho Terras, Estonian MEP and vice-chair of the European Parliament committee on Defence, tells Euronews' Radio Schuman today. Two days ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

The latest alliance – which kicks off with a 300 million yen purchase of Lifenet stock by the pharma company – adds yet another dimension to Eisai's beyond-the-pill strategy.

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price target of Yen4,200.00. The company’s shares closed ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s drug, Leqembi, after concluding a safety review. The European ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...